GSK's anti-BCMA therapy leads to updated PFS of 12 months

GlaxoSmithKline reported updated data after an additional 14 months of follow-up from the dose-expansion portion of the Phase I/II DREAMM-1 trial showing that

Read the full 232 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE